Back to Journals » Lung Cancer: Targets and Therapy » Volume 4

Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy

Authors Sugiura Y, Nemoto E, Kawai O, Ohkubo Y, Fusegawa H, Kaseda S

Received 13 March 2013

Accepted for publication 18 April 2013

Published 10 June 2013 Volume 2013:4 Pages 9—14


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Yasoo Sugiura,1 Etsuo Nemoto,1 Osamu Kawai,2 Yasuyuki Ohkubo,2 Hisae Fusegawa,2 Shizuka Kaseda1

1Department of Pulmonary and Thoracic Surgery, 2Department of Respiratory Medicine, Kanagawa National Hospital, Hadano, Japan

Background: Gefitinib is known as one of the agents for treating patients with both advanced lung cancer and an epidermal growth-factor receptor mutation. In the epidermal growth-factor receptor-mutant advanced non-small-cell lung cancer population, gefitinib therapy has been associated with increased response rate, longer progression-free survival, and better quality of life compared to other anticancer drugs. However, gefitinib has to be discontinued for patients in whom adverse events occur, even if it is still effective. Here, we retrospectively assessed the clinical course of patients receiving gefitinib therapy, with a particular focus on liver damage.
Patients and methods: Of 24 Asian patients treated with 250 mg gefitinib daily at Kanagawa National Hospital, Japan, between January 2008 and June 2012, grade 3 liver damage (Common Terminology Criteria for Adverse Events, version 4.0) occurred in nine and were eligible for our assessment. The regimen was subsequently changed to alternate-day administration. The relationships between liver damage and each clinical factor were retrospectively examined using Fisher’s exact test.
Results: Of the nine patients with liver damage, seven had previous exposure to another anticancer drug. There was a significant relationship between the incidence of liver damage and previous chemotherapy (P = 0.009). The objective response rates of patients treated with daily gefitinib 250 mg and alternate-day gefitinib following liver damage were 66.7% and 46.7%, respectively; these were not significantly different (P = 0.597).
Conclusion: Gefitinib for advanced adenocarcinoma patients who have previously undergone chemotherapy should be used cautiously and liver function monitored closely, because it frequently induces significant liver damage. The alternate-day administration of gefitinib may be a suitable option for patients in whom daily gefitinib therapy induces liver damage.

Keywords: gefitinib, liver damage, adjuvant chemotherapy, previous chemotherapy, alternate-day administration

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]